Impact of Force Control of Hip Abductor Muscles in Healthy Adults and Individuals With Parkinson'… (NCT07568951) | Clinical Trial Compass
RecruitingNot Applicable
Impact of Force Control of Hip Abductor Muscles in Healthy Adults and Individuals With Parkinson's Disease
Taiwan210 participantsStarted 2023-08-01
Plain-language summary
Both aging and Parkinson's disease (PD) negatively affect postural control and increase the risk of falls, with frontal plane balance being particularly challenging for these populations. While previous studies have mainly focused on sagittal plane balance, the contribution of hip abductor muscles remains unclear, especially regarding their force production and control abilities. Therefore, this study aims to investigate hip abductor muscle force production and force control, and to examine whether these factors are associated with postural control, gait, and balance performance in individuals across different ages and those with PD.
Who can participate
Age range
20 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Healthy people
Inclusion Criteria:
* 20 to 39 years (young), 40 to 59 years (young), and 60-85 years (old)
* generally in good health
* able to walk 10 m independently
* able to follow all instructions
Exclusion Criteria:
* neurologic, psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study
* any pain over the lower extremities
* uncontrolled cardiovascular diseases
* unable to provide informed consent.
PD
Inclusion Criteria:
* clinical diagnosis of idiopathic PD
* Hoehn and Yahr stages 1 to 3
* stable anti-PD medications
* able to walk 10 m independently
* able to follow all instructions
Exclusion Criteria:
* psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study
* neurological conditions other than PD
* any pain over the lower extremities
* uncontrolled cardiovascular diseases
* unable to provide informed consent.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.